R.D.K holdings S.A

Saturday, August 18, 2007

The Future of Fat Loss

Look good naked without stepping a foot in the gym.  That's
the new American dream right?  We are a nation obsessed
with the eternal quest to look great with minimal to no
effort.  Whether you are just too busy to make it to the
gym everyday, or simply need that little extra help with
your own diet and workout routine, there is good news on
the horizon for all of us, new drugs!  These upcoming
pharmaceutical releases are gearing up to take the fat loss
market by storm over the next couple of years so read up
and get a head start on your beach body competition.

Pramlintide - Already available in the U.S. as a diabetes
treatment, Pramlintide is being studied by Amylin
Pharmaceuticals for its ability to produce a feeling of
fullness when eating and reduce weight. A synthetic form of
a satiety hormone, research has shown that when it's
injected into people's bodies before a meal they eat less,
even when given foods they crave. Amylin is also looking at
how the drug works in combination with other hormones.

CP404 - CP404 is a calcium channel blocker that works as a
nasal spray to block olfactory activity, or our sense of
smell, and reduce food intake. Compellis Pharmaceuticals is
developing the drug, which has only been tested on mice so
far, says Compellis CEO Chris Adams. The company plans to
begin human testing this year.

Orlistat (Xenical and alli) - A lipase inhibitor, Orlistat
promotes weight loss by preventing the digestion and
absorption of some fat from food. Unabsorbed fat is then
excreted via the stool. It's available by prescription as
Xenical and, since June, as alli, the only FDA-approved
over-the-counter weight loss product. Orlistat side effects
may include gas with oily spotting and an urgent need to
have a bowel movement

CLA - A new meta-analysis by University of Wisconsin at
Madison researchers has shown that supplements containing
conjugated linoleic acid (CLA), on the market for years,
may help people shed fat. It's believed that CLA, a fatty
acid found in foods of animal origin such as beef, modifies
enzymes responsible for storing and burning fat.
Supplements are a good vehicle for CLA because it would be
difficult for people to get enough of the fatty acid
without loading up on saturated fat.

PP - Researchers at the Imperial College, London, are
looking at how gut hormones--pancreatic polypeptide (PP) in
particular--affect appetite control. The hormones are
released when a person eats, acting as neurotransmitters
that tell the brain to stop eating.  Though it's being
developed in the form of an injection, it's possible in the
future that it could be produced as a patch or gum.
Researchers hope to start phase one trials early next year
and get the drug on the market in three to five years.

Y2R blocker - Georgetown University Medical Center
researchers have been able to use nontoxic chemical
injections to add and remove fat from lab mice. To add fat,
researchers injected the neurotransmitter NPY into the
mice. It's believed that NPY is activated during stress,
causing apple-shaped obesity and metabolic syndrome. But
administration of the receptor Y2R into the mice's
abdominal fat prevented both results, melting the fat.
Researchers hope that blocking Y2R might work the same way
in humans.

Rimonabant (Acomplia) - Approved for use in the European
Union as an obesity treatment, rimonabant selectively
blocks the CB1 receptors of the endocannabinoid system.
This system of receptors in the brain and body helps
regulate food intake and how the body uses and stores fats
and sugars. In clinical trials, rimonabant has been shown
to reduce body weight, with side effects such as nausea and
anxiety. Sanofi-aventis withdrew its FDA new drug
application for rimonabant last month but is working toward
resubmitting.

Suppressing Rip140 - Research has shown that suppression of
receptor-interacting protein 140 (Rip140), a nuclear
hormone co-repressor that regulates fat accumulation, can
accelerate fat burning in animals and fat cells. Initially
the subject of experiments at Imperial College in London,
RXi Pharmaceuticals is developing the approach as a
potential obesity or type-2 diabetes treatment.

Cetilistat - Under development by Alizyme, Cetilistat is a
gastrointestinal lipase inhibitor that blocks fat digestion
and absorption, causing weight loss. Clinical trials have
shown that the drug has fewer side effects than Xenical,
according to Alizyme. Cetilistat is currently being
prepared for phase-three clinical development.

Meridia - An oral prescription medication, Meridia works by
affecting the appetite control center in the brain. Most
people who lose weight on the drug, in combination with
diet and exercise, do so in the first six months of
treatment, according to its maker, Abbott Laboratories.
Common side effects include headache, dry mouth,
constipation and insomnia.

So, have you scoped out the ones that sound like the next
big wonder drug?  Well don't get too excited, these need a
little more time before they are readily available to the
public but keep your eyes peeled for them over the next few
years.  And remember that being healthy is more than just a
weight game.  Be active, be fit, be healthy, and you will
look good naked.  The ultimate goal right?

----------------------------------------------------
This article is from the online marketing director of Fit
Fuel, Amber Thompson.  Fit Fuel is a leading natural and
organic foods retailer on the web (
http://www.FitFuel.com )